BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 208 filers reported holding BRIDGEBIO PHARMA INC in Q2 2021. The put-call ratio across all filers is 1.95 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $690 | +294.3% | 27,590 | +170.7% | 0.00% | +100.0% |
| Q2 2023 | $175 | +3.6% | 10,191 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $169 | +116.7% | 10,191 | 0.0% | 0.00% | – |
| Q4 2022 | $78 | -99.9% | 10,191 | 0.0% | 0.00% | -100.0% |
| Q3 2022 | $101,000 | +8.6% | 10,191 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $93,000 | -9.7% | 10,191 | 0.0% | 0.00% | – |
| Q1 2022 | $103,000 | -39.4% | 10,191 | 0.0% | 0.00% | -100.0% |
| Q4 2021 | $170,000 | -64.4% | 10,191 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $478,000 | -23.0% | 10,191 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $621,000 | -1.1% | 10,191 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $628,000 | – | 10,191 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |